Final results from the Randomized Phase II study of Z-Endoxifen and Tamoxifen in Endocrine Refractory, Estrogen Receptor Positive, HER2 negative Metastatic Breast Cancer (Alliance A011203)

Category Primary study
ConferenceSan Antonio Breast Cancer Symposium 2025
Year 2026
This article has no abstract
Epistemonikos ID: 181e0045fc5367d45f18e95874301f12dc9b9cd6
First added on: Jun 06, 2026